Enterprise Value

477.1M

Cash

230.3M

Avg Qtr Burn

-35.4M

Short % of Float

24.44%

Insider Ownership

4.39%

Institutional Own.

44.12%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

BLA

Resubmission

OMS906 Details
Paroxysmal nocturnal hemoglobinuria , Blood disorder

Phase 2

Data readout

Phase 2

Update

OMS1029 (MASP-2) Details
Lectin pathway disorder

Phase 1

Data readout

OMS527 (PDE7 inhibitor) Details
Movement disorder, Levodopa-induced dyskinesia associated with Parkinson’s disease, Cocaine use disorder, Addiction

Phase 1

Update

Narsoplimab (MASP-2 inhibitor, lectin pathway) Details
Kidney disease, Diabetic macular edema, Diabetes

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued